keyword
MENU ▼
Read by QxMD icon Read
search

Texas Biotech

keyword
https://www.readbyqxmd.com/read/29319690/texas-displays-silicon-valley-credentials-to-lure-brazilian-biotechs
#1
Melanie Senior
No abstract text is available yet for this article.
January 10, 2018: Nature Biotechnology
https://www.readbyqxmd.com/read/19332969/a-patented-strain-of-bacillus-coagulans-increased-immune-response-to-viral-challenge
#2
Mira Baron
BACKGROUND: Viral respiratory tract infection is the most common illness among humans. Probiotics have been known to enhance the immune system and, therefore, may represent a significant therapeutic advancement for treating viral respiratory tract infections. OBJECTIVE: A controlled study was conducted to evaluate the effects of the patented GanedenBC30 probiotic (Bacillus coagulans GBI-30, 6086, marketed as Sustenex [Ganeden Biotech, Inc., Mayfield Heights, OH]) on the immune system when exposed to adenovirus and influenza in otherwise healthy adults...
March 2009: Postgraduate Medicine
https://www.readbyqxmd.com/read/15609730/a-little-innovation-baylor-launches-biotech-firm-to-sell-cancer-therapy
#3
Paul Barr
No abstract text is available yet for this article.
November 15, 2004: Modern Healthcare
https://www.readbyqxmd.com/read/10388107/some-aim-to-fix-the-genes-themselves
#4
Waldholz
[The following article appeared in The Wall Street Journal, issue of May 6, 1998.] Ever since scientists learned over a decade ago that cancer is the result of defective genes, they have dreamed of shutting down tumor growth simply by replacing the bad genes with good ones. Researchers at two biotech companies and a pharmaceutical giant believe they are close to making that dream come true, at least for some patients. In two weeks, scientists will present results of several studies showing, for the first time, that cancer growth in severely sick patients can be stalled through an innovative method of repairing damaged genes...
1998: Oncologist
https://www.readbyqxmd.com/read/10287263/med-centers-breed-biotech-firms
#5
S Lutz
No abstract text is available yet for this article.
April 29, 1988: Modern Healthcare
https://www.readbyqxmd.com/read/10137060/managing-high-cost-and-biotech-drugs-two-institutions-perspectives
#6
W J Dana, B McWhinney
A proactive and multidisciplinary approach is used at The University of Texas MD Anderson Cancer Center to forecast the effect of new biotechnology and other high-cost agents prior to their commercial availability. Protocols, practice guidelines, and drug-use policies are developed to promote cost-effective use of these agents. To promote optimal utilization, two pharmacoeconomic strategies are used: cost reduction and drug performance. An economic impact analysis is performed on pending drug protocols, which includes hospital cost, patient billing, and estimates of insurance reimbursement denial risk...
September 1994: Hospital Formulary
https://www.readbyqxmd.com/read/8009464/the-emergence-of-texas-biotech
#7
M Richardson
No abstract text is available yet for this article.
April 1994: Texas Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"